BioLineRx (BLRX) vs CytoMed Therapeutics (GDTC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
BioLineRx (BLRX) has outperformed CytoMed Therapeutics (GDTC) over the past year, losing 49.8% versus a loss of 56.5%. CytoMed Therapeutics is the larger company by market cap ($11.3 million vs $11.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLRX | GDTC |
|---|---|---|
| Share price | $2.21 | $0.9449 |
| Market cap | $11.00M | $11.28M |
| 1-day change | +0.23% | -3.56% |
| YTD return | -20.22% | -29.22% |
| 1-year return | -49.77% | -56.46% |
| 5-year return | -98.19% | — |
| EPS (TTM) | $0.00 | $-0.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.50 | $3.68 |
| 52-week low | $2.15 | $0.68 |
| Distance from 52-week high | -50.89% | -74.32% |
| Analyst consensus | none | none |
| Avg. price target upside | +895.48% | +340.26% |
| Average volume | 16.27K | 78.66K |
| Shares outstanding | 4.98M | 11.93M |
| Employees | 20 | 42 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About BioLineRx
BLRX stock →BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.
Healthcare · Biotechnology · 20 employees
About CytoMed Therapeutics
GDTC stock →CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.
Healthcare · Biotechnology · 42 employees
BLRX vs GDTC FAQ
Which is bigger, BioLineRx or CytoMed Therapeutics?
CytoMed Therapeutics (GDTC) is larger, with a market capitalization of $11.28M compared with $11.00M for BioLineRx (BLRX).
Which stock has performed better over the past year, BLRX or GDTC?
BLRX returned -49.77% over the past 12 months, compared with -56.46% for GDTC (price return, excluding dividends). Past performance does not predict future results.
Are BioLineRx and CytoMed Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.